APA (7th ed.) Citation

H, G., J, Z., T, G., G, W., T, H., D, W., . . . C, G. (2026). RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma. Cancer immunology, immunotherapy : CII, 75(4), . https://doi.org/10.1007/s00262-026-04361-8

Chicago Style (17th ed.) Citation

H, Ge, Zhou J, Ghadban T, Wolters-Eisfeld G, Hackert T, Wang D, Liu W, and Güngör C. "RARRES1 Marks an Immune-cold, Chemoresistance-associated Malignant Epithelial Subpopulation Enriched in Pancreatic Ductal Adenocarcinoma." Cancer Immunology, Immunotherapy : CII 75, no. 4 (2026). https://doi.org/10.1007/s00262-026-04361-8.

MLA (9th ed.) Citation

H, Ge, et al. "RARRES1 Marks an Immune-cold, Chemoresistance-associated Malignant Epithelial Subpopulation Enriched in Pancreatic Ductal Adenocarcinoma." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 4, 2026, https://doi.org/10.1007/s00262-026-04361-8.